Trial Profile
An 8 Day, Randomised, Double Blind, 3-way Crossover Trial of Repeat Doses of Intranasal GSK256066 and Fluticasone Propionate in the Vienna Challenge Chamber in Subjects With Seasonal Allergic Rhinitis (SAR).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Fluticasone propionate (Primary) ; GSK 256066 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 09 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Mar 2008 New trial record.